Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
OTCMKTS:CRTPF

Cardiol Therapeutics (CRTPF) Stock Price, News & Analysis

→ Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad)
Free CRTPF Stock Alerts
$2.17
-0.19 (-8.05%)
(As of 05/17/2024 ET)
Compare
Today's Range
$2.13
▼
$2.40
50-Day Range
$1.39
▼
$2.36
52-Week Range
$1.48
▼
$4.19
Volume
345,211 shs
Average Volume
67,097 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChart
CRTPF stock logo

About Cardiol Therapeutics Stock (OTCMKTS:CRTPF)

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

CRTPF Stock Price History

CRTPF Stock News Headlines

May 16, 2024 | americanbankingnews.com
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Up 6.4%
February 15, 2024 | finance.yahoo.com
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
October 12, 2023 | benzinga.com
Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations
September 13, 2023 | finance.yahoo.com
Cardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
August 26, 2023 | theglobeandmail.com
Closing Bell: Cardiol Therapeutics Inc flat on Friday (CRDL)
August 18, 2023 | theglobeandmail.com
Cardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)
August 14, 2023 | theglobeandmail.com
Closing Bell: Cardiol Therapeutics Inc flat on Monday (CRDL)
August 8, 2023 | finance.yahoo.com
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
April 20, 2023 | theglobeandmail.com
Closing Bell: Cardiol Therapeutics Inc up on Thursday (CRDL)
November 11, 2022 | nasdaq.com
Here's Why Cardiol Therapeutics Inc. (CRDL) Could be Great Choice for a Bottom Fisher
September 24, 2022 | uk.finance.yahoo.com
Cardiol Therapeutics Inc. (CRDL)
May 19, 2022 | stockhouse.com
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors
January 19, 2022 | finance.yahoo.com
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
January 16, 2022 | nasdaq.com
Cardiol Therapeutics Inc - Class A Shares Close the Day 16.3% Higher - Daily Wrap
November 3, 2021 | reuters.com
Cardiol Therapeutics Inc
November 3, 2021 | marketwatch.com
Cardiol Therapeutics Shares Drop After Unit Offering Prices
October 26, 2021 | nasdaq.com
Cardiol Therapeutics Inc. (CRDL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
October 18, 2021 | marketwatch.com
Cardiol Therapeutics Expanding LANCER Trial, Shares Trading Higher
August 19, 2021 | finance.yahoo.com
When Will Cardiol Therapeutics Inc. (TSE:CRDL) Turn A Profit?
August 9, 2021 | msn.com
BRIEF-Cardiol Therapeutics To Commence Trading On Nasdaq Under Symbol "CRDL"
August 9, 2021 | proactiveinvestors.com
Cardiol Therapeutics receives final approval to list its common...
August 9, 2021 | finance.yahoo.com
Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"
August 6, 2021 | barrons.com
Cardiol Therapeutics Inc.
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:CRTPF
CUSIP
N/A
CIK
N/A
Web
www.cardiolrx.com
Phone
(289) 910-0850
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • David G. Elsley
    President, Chief Executive Officer & Director
  • Bernard Ching-Bing Lim
    Chief Operating Officer
  • Christopher J. Waddick
    Chief Financial Officer & Secretary
  • Anthony E. Bolton
    Director of Research
  • Andrew Hamer
    Chief Medical Officer

Key Competitors

View All Competitors

CRTPF Stock Analysis - Frequently Asked Questions

How have CRTPF shares performed in 2024?

Cardiol Therapeutics' stock was trading at $0.8432 on January 1st, 2024. Since then, CRTPF stock has increased by 157.4% and is now trading at $2.17.
View the best growth stocks for 2024 here.

How do I buy shares of Cardiol Therapeutics?

Shares of CRTPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CRTPF) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Urgent Nvidia Warning
Altimetry
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing